Advertisement

Topics

The Multiple Myeloma Research Consortium Company Profile

18:53 EDT 26th March 2019 | BioPortfolio

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, Washington University, Baylor Sammons Cancer Center, Sarah Cannon Cancer Center and Virginia Cancer Specialists. The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, with the help of the scientific community. The MMRC is an affiliate organization of the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas–genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit: www.themmrc.org.


News Articles [1222 Associated News Articles listed on BioPortfolio]

Unique Genetic Makeup of Myeloma Tumor Cells Profiled

Multiple myeloma is the second-most common type of blood cancer. Multiple myeloma occurs when plasma cells in the bone marrow,...

Current and Prospective Therapies Are Improving Outcomes in Relapsed Multiple Myeloma

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and revie...

Multiple Myeloma continues to be characterised by its unmet needs

Despite the latest advances in the treatment of multiple myeloma (MM), unmet needs abound in this difficult-to-treat oncology indication, despite...Read More... The post Multiple Myeloma continues to ...

Results from the EMN-011 trial, combination therapy for multiple myeloma

Prof Pieter Sonneveld speaks to ecancer at ASH 2018 about a clinical trail from the European Myeloma Network for newly diagnosed multiple myeloma, transplant eligible patients. He outlines the study ...

The MMRF CoMMpass Study Drives New Discoveries in Multiple Myeloma

NORWALK, Conn., Dec. 1, 2018 /PRNewswire/ -- Today, the Multiple Myeloma Research Foundation (MMRF) announced new discoveries driven by its landmark CoMMpass StudySM into defining Read more...

MRD Status a Superior Predictor of PFS in Multiple Myeloma?

The study also looks at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.

Expert Explains Latest Developments in Multiple Myeloma

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Advances offer Promise for Multiple Myeloma Patients

Dr. Bill Benisnger M.D. of Swedish Cancer Inst. discusses the growing number of treatment options for Multiple Myeloma

PubMed Articles [2484 Associated PubMed Articles listed on BioPortfolio]

Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis.

Multiple myeloma (MM) is a common malignancy belonging to the hematological system. The translocation t(4;14)(p16.3;q32.3) is a critical cytogenetic change of MM, which is presenting a poor prognosis....

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that co...

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring s...

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma.

To investigate the association between occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma (MM) in a large, consortium-based study.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Genetic variants in genes acting during the maturation process of immature B-cell to differentiated plasma cell could influence the risk of developing multiple myeloma (MM). During B-cell maturation, ...

Clinical Trials [5430 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

Companies [2042 Associated Companies listed on BioPortfolio]

The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, mo...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myelo...

More Information about "The Multiple Myeloma Research Consortium" on BioPortfolio

We have published hundreds of The Multiple Myeloma Research Consortium news stories on BioPortfolio along with dozens of The Multiple Myeloma Research Consortium Clinical Trials and PubMed Articles about The Multiple Myeloma Research Consortium for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Multiple Myeloma Research Consortium Companies in our database. You can also find out about relevant The Multiple Myeloma Research Consortium Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record